Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Mar;99(3):369–375. doi: 10.1111/j.1365-2249.1995.tb05560.x

Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

A M Jackson 1, A B Alexandroff 1, R W Kelly 1, A Skibinska 1, K Esuvaranathan 1, S Prescott 1, G D Chisholm 1, K James 1
PMCID: PMC1534215  PMID: 7882559

Abstract

Intravesical immunotherapy for carcinoma in situ of the bladder is arguably the most effective form of tumour immunotherapy described to date. Following repeated instillations of BCG organisms into the bladder, large quantities of cytokines are detected in patients' urine. This study concerns the production of IL-1 beta, IL-2, IL-4, IL-6, IL-8, IL-10, tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and soluble ICAM-1 (sICAM-1) throughout the six weekly instillations which comprise a therapeutic course. Sequential instillations of BCG induced secretion of IL-1 beta, IL-2, IL-6, IL-8, IL-10, TNF-alpha, IFN-gamma and sICAM-1 into urine. The responses were heterogeneous between patients and cytokines, but some general trends were evident. Although cytokine levels were initially low, their concentration increased with repeated instillation of BCG. Certain cytokines (e.g. IL-6, IL-8 and IL-10) could be detected after the first instillation, whilst others (e.g. IL-2 and IFN-gamma) were not detected until after the third or fourth instillation. Interestingly, IL-4 was not detected, perhaps suggesting a differential effect on Th2-like responses. Some patients produced particularly elevated or non-detectable levels of cytokines, and a positive correlation was found between the production of various cytokines. The production of a particular cytokine did not correspond with lack of production of another species. Whether monitoring the production of cytokines following therapy may be of prognostic value will be determined in a larger series of patients. However, as these potent immunomodulators are thought to be important for the 75% complete clinical response observed with BCG therapy, there remains the possibility that detection of the products of an activated immune system may correlate with eventual clinical outcome. This study is a necessary forerunner to full prognostic evaluation of such immunological data.

Full text

PDF
369

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allauzen S., Salhi S. L., Piechaczyk M., Bastide M., Pau B., Bouanani M. An efficient immunization protocol for production of monoclonal antibodies against soluble human insulin. Immunol Lett. 1994 Apr;40(1):1–6. doi: 10.1016/0165-2478(94)90197-x. [DOI] [PubMed] [Google Scholar]
  2. Bettex-Galland M., Studer U. E., Walz A., Dewald B., Baggiolini M. Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration. Eur Urol. 1991;19(2):171–175. doi: 10.1159/000473608. [DOI] [PubMed] [Google Scholar]
  3. Campbell S. C., Tanabe K., Alexander J. P., Edinger M., Tubbs R. R., Klein E. A. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects. J Urol. 1994 May;151(5):1385–1390. doi: 10.1016/s0022-5347(17)35265-5. [DOI] [PubMed] [Google Scholar]
  4. De Boer E. C., De Jong W. H., Steerenberg P. A., Aarden L. A., Tetteroo E., De Groot E. R., Van der Meijden A. P., Vegt P. D., Debruyne F. M., Ruitenberg E. J. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother. 1992;34(5):306–312. doi: 10.1007/BF01741551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. De Jong W. H., De Boer E. C., Van der Meijden A. P., Vegt P., Steerenberg P. A., Debruyne F. M., Ruitenberg E. J. Presence of interleukin-2 in urine of superficial bladder cancer patients after intravesical treatment with bacillus Calmette-Guérin. Cancer Immunol Immunother. 1990;31(3):182–186. doi: 10.1007/BF01744734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Denis M., Ghadirian E. IL-10 neutralization augments mouse resistance to systemic Mycobacterium avium infections. J Immunol. 1993 Nov 15;151(10):5425–5430. [PubMed] [Google Scholar]
  7. Fleischmann J. D., Toossi Z., Ellner J. J., Wentworth D. B., Ratliff T. L., Imbembo A. L. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. Cancer. 1989 Oct 1;64(7):1447–1454. doi: 10.1002/1097-0142(19891001)64:7<1447::aid-cncr2820640715>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  8. Flesch I. E., Hess J. H., Oswald I. P., Kaufmann S. H. Growth inhibition of Mycobacterium bovis by IFN-gamma stimulated macrophages: regulation by endogenous tumor necrosis factor-alpha and by IL-10. Int Immunol. 1994 May;6(5):693–700. doi: 10.1093/intimm/6.5.693. [DOI] [PubMed] [Google Scholar]
  9. Hawkyard S. J., Jackson A. M., James K., Prescott S., Smyth J. F., Chisholm G. D. The inhibitory effects of interferon gamma on the growth of bladder cancer cells. J Urol. 1992 May;147(5):1399–1403. doi: 10.1016/s0022-5347(17)37582-1. [DOI] [PubMed] [Google Scholar]
  10. Hawkyard S., James K., Prescott S., Jackson A. M., Ritchie A. W., Smyth J. F., Chisholm G. D. The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J Urol. 1991 May;145(5):1078–1081. doi: 10.1016/s0022-5347(17)38538-5. [DOI] [PubMed] [Google Scholar]
  11. Herr H. W., Laudone V. P., Badalament R. A., Oettgen H. F., Sogani P. C., Freedman B. D., Melamed M. R., Whitmore W. F., Jr Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol. 1988 Sep;6(9):1450–1455. doi: 10.1200/JCO.1988.6.9.1450. [DOI] [PubMed] [Google Scholar]
  12. Jackson A. M., Alexandroff A. B., McIntyre M., Esuvaranathan K., James K., Chisholm G. D. Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy. J Clin Pathol. 1994 Apr;47(4):309–312. doi: 10.1136/jcp.47.4.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jackson A. M., Alexandrov A. B., Gribben S. C., Esuvarnathan K., James K. Expression and shedding of ICAM-1 in bladder cancer and its immunotherapy. Int J Cancer. 1993 Dec 2;55(6):921–925. doi: 10.1002/ijc.2910550608. [DOI] [PubMed] [Google Scholar]
  14. Jackson A. M., Alexandrov A. B., Prescott S., James K., Chisholm G. D. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-gamma and tumour necrosis factor-alpha. J Urol. 1992 Nov;148(5):1583–1586. doi: 10.1016/s0022-5347(17)36974-4. [DOI] [PubMed] [Google Scholar]
  15. Jackson A. M., Alexandrov A. B., Prescott S., James K., Chisholm G. D. Role of adhesion molecules in lymphokine-activated killer cell killing of bladder cancer cells: further evidence for a third ligand for leucocyte function-associated antigen-1. Immunology. 1992 Jun;76(2):286–291. [PMC free article] [PubMed] [Google Scholar]
  16. Jackson A. M., Prescott S., Hawkyard S. J., James K., Chisholm G. The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical evans BCG therapy. Cancer Immunol Immunother. 1993;36(1):25–30. doi: 10.1007/BF01789127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lamm D. L. Carcinoma in situ. Urol Clin North Am. 1992 Aug;19(3):499–508. [PubMed] [Google Scholar]
  18. Lattime E. C., Gomella L. G., McCue P. A. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res. 1992 Aug 1;52(15):4286–4290. [PubMed] [Google Scholar]
  19. Lemonde P., Dubreuil R., Guindon A., Lussier G. Stimulating influence of bacillus Calmette-Guérin on immunity to polyoma tumors and spontaneous leukemia. J Natl Cancer Inst. 1971 Nov;47(5):1013–1024. [PubMed] [Google Scholar]
  20. Prescott S., James K., Busuttil A., Hargreave T. B., Chisholm G. D., Smyth J. F. HLA-DR expression by high grade superficial bladder cancer treated with BCG. Br J Urol. 1989 Mar;63(3):264–269. doi: 10.1111/j.1464-410x.1989.tb05187.x. [DOI] [PubMed] [Google Scholar]
  21. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992 Jun;147(6):1636–1642. doi: 10.1016/s0022-5347(17)37668-1. [DOI] [PubMed] [Google Scholar]
  22. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F. Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol. 1990 Nov;144(5):1248–1251. doi: 10.1016/s0022-5347(17)39713-6. [DOI] [PubMed] [Google Scholar]
  23. Ratliff T. L., Haaff E. O., Catalona W. J. Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol. 1986 Aug;40(2):375–379. doi: 10.1016/0090-1229(86)90043-7. [DOI] [PubMed] [Google Scholar]
  24. Ratliff T. L., Ritchey J. K., Yuan J. J., Andriole G. L., Catalona W. J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol. 1993 Sep;150(3):1018–1023. doi: 10.1016/s0022-5347(17)35678-1. [DOI] [PubMed] [Google Scholar]
  25. Utz D. C., Farrow G. M., Rife C. C., Segura J. W., Zincke H. Carcinoma in situ of the bladder. Cancer. 1980 Apr 15;45(7 Suppl):1842–1848. [PubMed] [Google Scholar]
  26. Utz D. C., Hanash K. A., Farrow G. M. The plight of the patient with carcinoma in situ of the bladder. J Urol. 1970 Feb;103(2):160–164. doi: 10.1016/s0022-5347(17)61913-x. [DOI] [PubMed] [Google Scholar]
  27. Wang S. C., Morel P. A., Wang Q., Jordan M. L., Simmons R. L., Tweardy D. J. A dual mechanism of immunosuppression by FK-506. Differential suppression of IL-4 and IL-10 levels in T helper 2 cells. Transplantation. 1993 Oct;56(4):978–985. doi: 10.1097/00007890-199310000-00038. [DOI] [PubMed] [Google Scholar]
  28. el-Demiry M. I., Smith G., Ritchie A. W., James K., Cumming J. A., Hargreave T. B., Chisholm G. D. Local immune responses after intravesical BCG treatment for carcinoma in situ. Br J Urol. 1987 Dec;60(6):543–548. doi: 10.1111/j.1464-410x.1987.tb05039.x. [DOI] [PubMed] [Google Scholar]
  29. van der Meijden A. P., Steerenberg P. A., de Jong W. H., Debruyne F. M. Intravesical Bacillus Calmette-Guérin treatment for superficial bladder cancer: results after 15 years of experience. Anticancer Res. 1991 May-Jun;11(3):1253–1258. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES